medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2017-14-67-76medsovet-2169Research ArticleХимиотерапия злокачественных опухолейMalignant tumor chemotherapyХИМИОТЕРАПИЯ В ЛЕЧЕНИИ ЛОКАЛИЗОВАННОГО И МЕТАСТАТИЧЕСКОГО РАКА ТОЛСТОЙ КИШКИ: НОВОЕ И ЕЩЕ НЕ ЗАБЫТОЕ СТАРОЕCHEMOTHERAPY IN THE MANAGEMENT OF LOCALIZED AND METASTATIC COLON CANCER: NEW AND YET UNFORGOTTEN APPROACHESДоброваН. В.DobrovaN. V.

Кандидат медицинских наук.

Москва

PhD in medicine.

Moscow

ГордееваО. О.GordeevaO. O.ЧерноглазоваЕ. В.ChernoglazovaE. V.

Кандидат медицинских наук.

Москва

PhD  in medicine.

Moscow

ТрякинА. А.TryakinA. A.

Доктор медицинских наук.

Москва

MD.

Moscow

Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина Минздрава РоссииРоссияBlokhin Russian Cancer Research Centre of the Ministry of HealthRussian Federation2017141120170146776Copyright © Доброва Н.В., Гордеева О.О., Черноглазова Е.В., Трякин А.А., 20172017Доброва Н.В., Гордеева О.О., Черноглазова Е.В., Трякин А.А.Dobrova N.V., Gordeeva O.O., Chernoglazova E.V., Tryakin A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2169

За  последние  пару  десятков  лет  мы  стали свидетелями  существенного прогресса  в  лечении  метастатического колоректального рака: появление новых таргетных  препаратов и дифференцированного подхода  к их назначению, расширение показаний к резекции метастазов в печени и легких привели к увеличению продолжительности  жизни пациентов этой группы. Тем не менее  химиотерапия остается основой лекарственного лечения рака толстой кишки. В данной работе мы рассматриваем ряд новых подходов, касающихся применения химиотерапии при III  и IV стадиях заболевания.

Over the course of the past couple of decades, we have witnessed some significant improvements in the treatment of metastatic colorectal cancer: the emergence of novel targeted drugs and a differentiated approach to their administration, the extension of indications for surgical resection for liver and lungs metastases has resulted in the increased life expectancy among patients in this group. Nevertheless, chemotherapy remains the treatment of choice for colon cancer. In this paper, we discuss new approaches to the use of chemotherapy on stages III and IV of colorectal cancer.

метастатический колоректальный ракрак толстой кишкихимиотерапияоксалиплатин5-фторурацилиринотеканmetastatic colorectal cancercolon cancerchemotherapyOxaliplatin5-fluorouracilIrinotecanReferencesКаприн А.Д., Старинский В. В., Петрова Г. В. (ред.). Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). М.: ФГБУ «МНИОИ им. П. А. Герцена» Минздрава России, 2016. 250 с.Каприн А.Д., Старинский В. В., Петрова Г. В. (ред.). Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). М.: ФГБУ «МНИОИ им. П. А. Герцена» Минздрава России, 2016. 250 с.Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer, 2015, Mar 1, 136(5): E359-86.Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer, 2015, Mar 1, 136(5): E359-86.de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J. Clin. Oncol., 1997, 15(2): 808-815.de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J. Clin. Oncol., 1997, 15(2): 808-815.Kohne C-H, Wils J, Lorenz M, Schoffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg U, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Ruckle H, Lichinitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ. Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J. Clin. Oncol., 2003, 21(20): 3721-3728.Kohne C-H, Wils J, Lorenz M, Schoffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg U, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Ruckle H, Lichinitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ. Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J. Clin. Oncol., 2003, 21(20): 3721-3728.Thirion P, Michielis S, Pignon JP, Buyse M, Braud AC, Carlson RW, O´Connell M, Sargent P, Piedbois P, Meta-analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an update metaanalysis. J. Clin. Oncol., 2004, 22(18): 3766-3775.Thirion P, Michielis S, Pignon JP, Buyse M, Braud AC, Carlson RW, O´Connell M, Sargent P, Piedbois P, Meta-analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an update metaanalysis. J. Clin. Oncol., 2004, 22(18): 3766-3775.Giantonio B, Catalano P, Meropol N, O’Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd, Eastern Cooperative Oncology Group Study E3200. Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol., 2007, 20: 1539-1544.Giantonio B, Catalano P, Meropol N, O’Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd, Eastern Cooperative Oncology Group Study E3200. Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol., 2007, 20: 1539-1544.Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tian Y, Sidhu R. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann. Oncol., 2014, 25(1): 107-16.Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tian Y, Sidhu R. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann. Oncol., 2014, 25(1): 107-16.Shi Q, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Sougklakos I, Kerr R, Labianca R, Meyerhardt JA, Bonnetain F, Watanabe T, Boukovinas I, Renfro LA, Grothey A, Niedzwiecki D, Torri V, Andre T, Sargent DJ, Iveson T. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. J. Clin. Oncol., 2017, 35(suppl, abstr LBA1).Shi Q, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Sougklakos I, Kerr R, Labianca R, Meyerhardt JA, Bonnetain F, Watanabe T, Boukovinas I, Renfro LA, Grothey A, Niedzwiecki D, Torri V, Andre T, Sargent DJ, Iveson T. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. J. Clin. Oncol., 2017, 35(suppl, abstr LBA1).Nordlinger B, Sorbye H, Glimelius B et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC40983): longterm results of a randomised, controlled, phase 3 trial. Lancet Oncol, 2013, 14(12): 1208-1215.Nordlinger B, Sorbye H, Glimelius B et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC40983): longterm results of a randomised, controlled, phase 3 trial. Lancet Oncol, 2013, 14(12): 1208-1215.Sorbye H, Mauer M, Gruenberger T et al. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann. Surg., 2012, 255(3): 534-539.Sorbye H, Mauer M, Gruenberger T et al. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann. Surg., 2012, 255(3): 534-539.Adam R, Bhangui P, Poston G et al. Is perioperative chemotherapyuseful for solitary, metachronous, colorectal liver metastases? Ann. Surg., 2010, 252(5): 774-787.Adam R, Bhangui P, Poston G et al. Is perioperative chemotherapyuseful for solitary, metachronous, colorectal liver metastases? Ann. Surg., 2010, 252(5): 774-787.Zhu D, Zhong Y, Wei Y et al. Effect of neoadjuvantchemotherapy in patients with resectable colorectal liver metastases. PLoS One, 2014, 9(1): e86543.Zhu D, Zhong Y, Wei Y et al. Effect of neoadjuvantchemotherapy in patients with resectable colorectal liver metastases. PLoS One, 2014, 9(1): e86543.John Primrose et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. The Lancet Oncology, 2014 May, 15(6): 601-611.John Primrose et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. The Lancet Oncology, 2014 May, 15(6): 601-611.Falcone A, Ricci S, Brunetti C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaloplatin, and irinotecan (FOLFOXIRI) compared to infusionalfluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer. J. Clin. Oncol., 2015, 25: 1670-76.Falcone A, Ricci S, Brunetti C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaloplatin, and irinotecan (FOLFOXIRI) compared to infusionalfluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer. J. Clin. Oncol., 2015, 25: 1670-76.Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated onerallsurvivaland molecular subgroup analy sis of the open-label, phase 3 TRIBE study. Lancet Oncol, 2015, 16: 1306-15.Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated onerallsurvivaland molecular subgroup analy sis of the open-label, phase 3 TRIBE study. Lancet Oncol, 2015, 16: 1306-15.Schmoll H-J, Garlipp B, Junghanss C et al. CHARTA: FOLFOX+bevacizumab +/irinotecan in advanced colorectal cancer (CRC). Final results of the randomized phase II trial of the AIO (KRK 0209).Schmoll H-J, Garlipp B, Junghanss C et al. CHARTA: FOLFOX+bevacizumab +/irinotecan in advanced colorectal cancer (CRC). Final results of the randomized phase II trial of the AIO (KRK 0209).Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict longterm survival. Ann. Surg., 2004, 240(4): 644-657.Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict longterm survival. Ann. Surg., 2004, 240(4): 644-657.Adam R, Wicherts DA, Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J. Clin. Oncol., 2009, 27(11): 1829-1835.Adam R, Wicherts DA, Haas RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J. Clin. Oncol., 2009, 27(11): 1829-1835.Folprecht G, Grothey A, Alberts S et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann. Oncol., 2005, 16(8): 1311-1319.Folprecht G, Grothey A, Alberts S et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann. Oncol., 2005, 16(8): 1311-1319.Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol., 2004, 22: 229-237.Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol., 2004, 22: 229-237.Arkenau HT, Arnold D, Cassidy J et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/ leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J. Clin. Oncol., 2008, 26(36): 5910-5917.Arkenau HT, Arnold D, Cassidy J et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/ leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J. Clin. Oncol., 2008, 26(36): 5910-5917.Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J. Clin. Oncol., 2007, 25(30): 4779-4786.Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J. Clin. Oncol., 2007, 25(30): 4779-4786.Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann. Surg., 2004, 240(4): 644-657.Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann. Surg., 2004, 240(4): 644-657.Baize N, Gerard B, Bleiberg H et al.Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases. Gastroenterol. Clin. Biol., 2006, 30: 1349-1353.Baize N, Gerard B, Bleiberg H et al.Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases. Gastroenterol. Clin. Biol., 2006, 30: 1349-1353.Gruenberger T, Bridgewater JA, Chau I et al. Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: resectability and safety in OLIVIA. Jour. Of Clin. Oncol., 2013, 31(15, suppl.): 3619.Gruenberger T, Bridgewater JA, Chau I et al. Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: resectability and safety in OLIVIA. Jour. Of Clin. Oncol., 2013, 31(15, suppl.): 3619.Masi G, Loupakis F, Pollina L et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/ leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann. Surg., 2009, 249: 420-425.Masi G, Loupakis F, Pollina L et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/ leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann. Surg., 2009, 249: 420-425.Ychou M, Viret F, Kramar A et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemoth. Pharmacol., 2008, 62(2): 195-201.Ychou M, Viret F, Kramar A et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemoth. Pharmacol., 2008, 62(2): 195-201.Vasile E, Masi G, Fornaro L et al. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. Br. J. Cancer., 2009, 100(11): 1720-1724.Vasile E, Masi G, Fornaro L et al. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. Br. J. Cancer., 2009, 100(11): 1720-1724.Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol., 2007, 25(13): 1670-1676.Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol., 2007, 25(13): 1670-1676.Kemeny N, Capanu M, D’Angelica M et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Annals of Oncology, 2009, 20: 1236–1241.Kemeny N, Capanu M, D’Angelica M et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Annals of Oncology, 2009, 20: 1236–1241.Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, BergslandE.Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003 Jan 1, 21(1): 60-5.Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, BergslandE.Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003 Jan 1, 21(1): 60-5.Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF.Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol, 2005 Jun 1, 23(16): 3697-705.Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B, Novotny WF.Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol, 2005 Jun 1, 23(16): 3697-705.Saunders MP, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin D, Jonker DJ, Stuart Osborne, Markus Loeffler, Daniel Waterkamp, David Cunningham. Efficacy and safety according to age subgroups in AVEX, a randomized phase III trial of bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer. J. Clin. Oncol., 2013 May.Saunders MP, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin D, Jonker DJ, Stuart Osborne, Markus Loeffler, Daniel Waterkamp, David Cunningham. Efficacy and safety according to age subgroups in AVEX, a randomized phase III trial of bevacizumab in combination with capecitabine for the first-line treatment of elderly patients with metastatic colorectal cancer. J. Clin. Oncol., 2013 May.Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol, 2004, 22: 1209–14.Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol, 2004, 22: 1209–14.Koopman M, Seymour Mt, Punt Cj. The CAIRO and FOCUS studies: which lesson is to be learned? Oncologist, 2009, 14: 192-193, author reply 194-196.Koopman M, Seymour Mt, Punt Cj. The CAIRO and FOCUS studies: which lesson is to be learned? Oncologist, 2009, 14: 192-193, author reply 194-196.Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet, 2007, 370: 135-142.Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet, 2007, 370: 135-142.Seymour MT, Maughan TS, Ledermann Ja et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet, 2007, 370: 143-152.Seymour MT, Maughan TS, Ledermann Ja et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet, 2007, 370: 143-152.Modest Dominik, Fischer von Weikersthal Ludwig, Decker Thomas, Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011) – study. Annals of Oncology, 2017, 28(Supple 3): 147-148Modest Dominik, Fischer von Weikersthal Ludwig, Decker Thomas, Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011) – study. Annals of Oncology, 2017, 28(Supple 3): 147-148А De Cramont et al. Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy. J Clin Oncol, 2009, 27(15 Suppl.): 4024.А De Cramont et al. Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy. J Clin Oncol, 2009, 27(15 Suppl.): 4024.Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapybe discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol, 2009, 27: 572733.Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapybe discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol, 2009, 27: 572733.Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomizedstudy of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-gofashion in advanced colorectal cancer – a GERCOR study. J Clin Oncol, 2006, 24: 394-400.Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomizedstudy of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-gofashion in advanced colorectal cancer – a GERCOR study. J Clin Oncol, 2006, 24: 394-400.Adams RA, Meade AM, Seymour MT, et al. Intermittent versus continuousoxaliplatin and fluoropyrimidine combination chemotherapyfor first-line treatment of advanced colorectal cancer: resultsof the randomised phase 3 MRC COIN trial. Lancet Oncol, 2011, 12: 642-53.Adams RA, Meade AM, Seymour MT, et al. Intermittent versus continuousoxaliplatin and fluoropyrimidine combination chemotherapyfor first-line treatment of advanced colorectal cancer: resultsof the randomised phase 3 MRC COIN trial. Lancet Oncol, 2011, 12: 642-53.Labianca R, Sobrero A, Isa L, et al. Intermittent versus continuouschemotherapy in advanced colorectal cancer: a randomized ‘GISCAD’ trial. Ann Oncol, 2011, 22: 1236-42.Labianca R, Sobrero A, Isa L, et al. Intermittent versus continuouschemotherapy in advanced colorectal cancer: a randomized ‘GISCAD’ trial. Ann Oncol, 2011, 22: 1236-42.Luo HY, Li YH, Wang W et al. Single-Agent Capecitabineas Maintenance Therapy AfterInduction of XELOX (or FOLFOX) in FirstLineTreatment of Metastatic Colorectal Cancer: Randomizedclinical trial of efficacy and safety. Chin J Cancer, 2016, 35: 13.Luo HY, Li YH, Wang W et al. Single-Agent Capecitabineas Maintenance Therapy AfterInduction of XELOX (or FOLFOX) in FirstLineTreatment of Metastatic Colorectal Cancer: Randomizedclinical trial of efficacy and safety. Chin J Cancer, 2016, 35: 13.Simkens LH, van Tinteren H, May A et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet, 2015, 385: 1843-1852.Simkens LH, van Tinteren H, May A et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet, 2015, 385: 1843-1852.André T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. N Engl J Med, 2004 Jun 3, 350(23): 2343-51.André T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. N Engl J Med, 2004 Jun 3, 350(23): 2343-51.Mols F, Beijers T, Lemmens V et al. Chemotherapy-Induced Neuropathy and Its AssociationWith Quality of Life Among 2to 11-Year Colorectal Cancer Survivors: Results From the Population-Based PROFILES Registry. J Clin Oncol, 2013 Jul 20, 31(21): 2699-707.Mols F, Beijers T, Lemmens V et al. Chemotherapy-Induced Neuropathy and Its AssociationWith Quality of Life Among 2to 11-Year Colorectal Cancer Survivors: Results From the Population-Based PROFILES Registry. J Clin Oncol, 2013 Jul 20, 31(21): 2699-707.Durand JP, Deplanque G, Montheil V et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Annals of Oncology, 2012, 23: 200–205.Durand JP, Deplanque G, Montheil V et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Annals of Oncology, 2012, 23: 200–205.Zimmerman C, Atherton PJ, Pachman D et al. MC11C4: a pilot randomized, placebo-controlled, double-blindstudy of venlafaxine to prevent oxaliplatin-induced neuropathy. Support Care Cancer, 2016 Mar, 24(3): 1071-8.Zimmerman C, Atherton PJ, Pachman D et al. MC11C4: a pilot randomized, placebo-controlled, double-blindstudy of venlafaxine to prevent oxaliplatin-induced neuropathy. Support Care Cancer, 2016 Mar, 24(3): 1071-8.Salehi Z, Roayaei M. Effect of Vitamin E on Oxaliplatin-induced Peripheral Neuropathy Prevention: A Randomized Controlled Trial. Int J Prev Med, 2015 Nov 2, 6: 104.Salehi Z, Roayaei M. Effect of Vitamin E on Oxaliplatin-induced Peripheral Neuropathy Prevention: A Randomized Controlled Trial. Int J Prev Med, 2015 Nov 2, 6: 104.de Andrade D, Teixeira M J, Galhardoni R et al. Pregabalin for the Prevention of OxaliplatinInduced Painful Neuropathy: A Randomized, Double-Blind Trial. Oncologist, 2017 Jun 26. pii: theoncologist. 2017-0235.de Andrade D, Teixeira M J, Galhardoni R et al. Pregabalin for the Prevention of OxaliplatinInduced Painful Neuropathy: A Randomized, Double-Blind Trial. Oncologist, 2017 Jun 26. pii: theoncologist. 2017-0235.Esfahani A, Somi M, Ayromlou H et al. The effect of n-3 polyunsaturated fattyacids on incidence and severity ofoxaliplatin induced peripheral neuropathy: a randomized controlled trial. Biomark Res, 2016 Jun 23, 4: 13.Esfahani A, Somi M, Ayromlou H et al. The effect of n-3 polyunsaturated fattyacids on incidence and severity ofoxaliplatin induced peripheral neuropathy: a randomized controlled trial. Biomark Res, 2016 Jun 23, 4: 13.Jordan B, Jahn F, Beckmann J et al. Calcium and Magnesium Infusions for thePrevention of Oxaliplatin-Induced Peripheral Neurotoxicity. A Systematic Review Oncology, 2016, 90(6): 299-306.Jordan B, Jahn F, Beckmann J et al. Calcium and Magnesium Infusions for thePrevention of Oxaliplatin-Induced Peripheral Neurotoxicity. A Systematic Review Oncology, 2016, 90(6): 299-306.Hochster H, Grothey A, Hart L, et al. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of the CONcePT trial. Ann Oncol, 2014, 25: 1172–1178.Hochster H, Grothey A, Hart L, et al. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of the CONcePT trial. Ann Oncol, 2014, 25: 1172–1178.Gamelin L, Boisdron-Celle M, Morel A, et al. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusionand no impact on its efficacy. J Clin Oncol, 2008, 26: 1188–1189, author reply 1189–1190.Gamelin L, Boisdron-Celle M, Morel A, et al. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusionand no impact on its efficacy. J Clin Oncol, 2008, 26: 1188–1189, author reply 1189–1190.

The authors declare that there are no conflicts of interest present.